Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has unveiled plans to initiate a phase I clinical trial for E2012, a gamma secretase modulator being evaluated as a potential new treatment for Alzheimer's disease.
Subscribe to our email newsletter
Gamma secretase plays a role in the production of beta-amyloid, a major component of plaque in the brain, which is thought to be a cause of Alzheimer’s disease.
E2012 is a new chemical entity discovered by Eisai and, in preclinical research, has shown some potential to reduce the production of beta-amyloid by modulating the function of gamma secretase. E2012 and its effect on beta-amyloid will now be evaluated in people.
“As a leader in Alzheimer’s disease therapy, in part through its marketed drug, Aricept, Eisai is pursuing a multi-faceted approach to Alzheimer’s disease research that includes investigating genes responsible for the onset of the disease, immunotherapy and vaccine therapy,” said the company in a statement.